Table 4.
Studies with cerebral vasospasm (CVS) after aneurysmal subarachnoid haemorrhage (SAH) and intra-arterial nimodipine (IAN) treatment.
| CG | Pat | AI | CI | Infarct | mRS 0–2/GOS >4 | mRS 0–2 (3–10 m) | Mortality in hosp/30 d | CVS onset d after SAH | Complication | |
|---|---|---|---|---|---|---|---|---|---|---|
| Biondi et al., 2004 19 | No | 25 | 43 % | 76 % | – | – | 3–6 m: 72% | 2 (8%) | Mean 7 ± 3 days | No |
| Hänggi et al., 2008 13 | No | 18 | 77 % | 11 % | 61 % | 61 % | 3 m: 61 % | 1 (5%) | – | No |
| Kim et al., 2009 14 | No | 19 | 79 % | 68 % | – | 79 % | – | 0 (0%) | Mean 9.6 ± 3.1 | No |
| Cho et al., 2011 15 | No | 42 | 82 % | 68 % | 21 % | 76 % | 6 m: 85 % | 1 (2%) | 3 (3% of procedures) | |
| Bashir et al., 2016 1 | No | 25 | 96 % | 12 % | 48 % | 4 % | 3 m: 20% | 9 (36%) | Median 8 | No |
| Andereggen et al., 2017 20 | Yes, 52 | 31 | 31 % | – | 61 % | 25 % | 10 m: 60% | 16 (20%) | – | 5 (16% of pat) |
| Ditz et al., 2018 17 | Yes, 15 | 15 | 93 % | – | 47 % | 0 % | 3/6 m: 12%/36% | 1 (7%) | Median 6 (0–10) | 1 (1.5% of procedures) |
| Our study, 2020 | Yes, 7 | 48 | – | – | 60 % | 25 % | 6 m: 47% | 2 (4%)/4 (8%) | Median 5 (0–30) | 10 (21% of pat, 8% of procedures |
AI: angiographic improvement; CG: control group; CI: clinical improvement; CVS: cerebral vasospasm; d: days; GOS: Glasgow Outcome Scale; hosp: hospital; infarct: infarct related to vasospasm; m: months; mRS: modified Rankin Scale; pat: number of patients.
Symbol - indicates no information.